2022 Presenting Companies
Genprex -ONSITE PRESENTER
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies with large market opportunities for patients with cancer and diabetes. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC), with each of these clinical programs receiving a Fast Track Designation from the Food and Drug Administration, and for small cell lung cancer (SCLC). GPX-002 is an exclusively licensed proprietary gene therapy product Genprex is developing for diabetes using a novel delivery technology. Genprex’s diabetes gene therapy approach is comprised of an infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. In models of T1D, the genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In T2D, where autoimmunity is not at play, it is believed that exhausted beta cells are also rejuvenated and replenished.